Development and qualification of a representative scale-down model of automated Ficoll-based processing of a cell-based therapeutic according to quality by design principles.

Autor: Sanjuan-Gimenez JC; Ixaka Iberia, Seville, Spain., Morales ML; Ixaka Iberia, Seville, Spain., Carranza-Garcia I; Ixaka Iberia, Seville, Spain., Pino-Zumaquero AD; Ixaka Iberia, Seville, Spain., Hernández-Ruiz L; Ixaka Iberia, Seville, Spain., Villegas E; Ixaka Iberia, Seville, Spain. Electronic address: enrique.villegas@ixaka.com.
Jazyk: angličtina
Zdroj: Cytotherapy [Cytotherapy] 2021 Oct; Vol. 23 (10), pp. 953-959. Date of Electronic Publication: 2021 Jul 03.
DOI: 10.1016/j.jcyt.2021.04.008
Abstrakt: Background Aims: This article describes the development of a small-scale model for Ficoll-based cell separation as part of process development of an advanced therapy medicinal product and its qualification. Because of the complexity of biological products, their manufacturing process as well as characterization and control needs to be accurately understood. Likewise, scale-down models serve as an indispensable tool for process development, characterization, optimization and validation. This scale-down model represents a cell processor device widely used in advance therapies. This approach is inteded to optimise resources and to focus its use on process characterisation studies under the paradigm of the Quality by design. A scale-down model should reflect the large manufacturing scale. Consequently, this simplified system should offer a high degree of control over the process parameters to depict a robust model, even considering the process limitations. For this reason, a model should be developed and qualified for the intended purpose.
Methods: Process operating parameters were studied, and their resulting performance at full scale was used as a baseline to guide scale-down model development. Once the model was established, comparability runs were performed by establishing standard operating conditions with bone marrow samples. These analyses showed consistency between the bench and the large scale. Additionally, statistical analyses were employed to demonstrate equivalence.
Results: The process performance indicators and assessed quality attributes were equivalent and fell into the acceptance ranges defined for the large-scale process.
Conclusions: This scale-down model is suitable for use in process characterization studies.
Competing Interests: Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.
(Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: